spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Cell Therapeutics 

 HSMN NewsFeed - 12 Jul 2023
BrainStorm Cell Therapeutics Appoints Bob Dagher, M.D., as Executive Vice President and Chief Development Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Mar 2023
BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn(R) for the Treatment of ALS
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 27 Dec 2022
BrainStorm Cell Therapeutics Announces Type A Meeting with FDA Granted for NurOwn(R)
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 10 Nov 2022
BrainStorm Cell Therapeutics Receives Refusal to File Letter from FDA for its New Biologics License Application for NurOwn for the treatment of ALS
Biopharmaceuticals Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 15 Sep 2022
BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal
Regenerative Medicine Neurology
 HSMN NewsFeed - 9 May 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Dec 2021
FDA Authorizes Further NurOwn(R) Dosing Under Expanded Access Program
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 8 Nov 2021
BrainStorm Cell Therapeutics Expands Leadership Team to Support Clinical Development and Medical Affairs
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 18 Oct 2021
NeuExcell Therapeutics names Lori Gavrin as Chief Business and Strategy Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Aug 2021
NeuExcell Therapeutics Raises $10+ Million Series Pre-A Round To Continue Its Company Growth
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 11 Aug 2021
GentiBio Announces $157M Series A Financing to Advance Engineered Regulatory T cells as Transformative Therapeutics with Potential to Restore Immune Tolerance and Durably Treat Autoinflammation
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 24 May 2021
Stemedica Signs License Agreement with Pulthera, LLC for all Respiratory Indications including those related to COVID-19
Regenerative Medicine Licensing
 HSMN NewsFeed - 10 Feb 2021
AbbVie and Caribou Biosciences Announce Collaboration and License Agreement for CAR-T Cell Products
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 14 Dec 2020
BrainStorm Announces NurOwn(R) Expanded Access Program
Regenerative Medicine Neurology Product Launch
 HSMN NewsFeed - 23 Nov 2020
BrainStorm to present NurOwn(R) Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND
Regenerative Medicine Neurology
 HSMN NewsFeed - 17 Nov 2020
Celularity Announces Appointments of Chief Medical Officer and Senior Vice President of Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Nov 2020
BrainStorm Announces Topline Results from NurOwn(R) Phase 3 ALS Study
Regenerative Medicine Neurology
 HSMN NewsFeed - 2 Nov 2020
CARsgen Therapeutics Closes a USD 186 Million Series C Equity Financing to Accelerate Global Clinical Trials of its Cell Therapy Product Candidates
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Aug 2020
ImmPACT Bio USA Inc. Raises $18 Million In Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 24 Jun 2020
BrainStorm Expands Clinical Pipeline to Evaluate NurOwn(R) for the Treatment of Alzheimer's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 27 May 2020
BrainStorm Appoints Pharmaceutical Veteran Stacy R. Lindborg, Ph.D. as Executive Vice President, Head of Global Clinical Research
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 27 Apr 2020
CARsgen Therapeutics Receives Positive EMA Opinion on Orphan Drug Designation for Fully Human Anti-BCMA CAR-T Cells (CT053) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 22 Jan 2020
Celularity Announces FDA Clearance of Landmark IND for CYNK-001, an Allogeneic, Off-the-Shelf Cryopreserved NK Cell Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2019
Aspen Neuroscience Launches With $6.5 Million Seed Funding to Advance First-of-its-Kind Personalized Cell Therapy for Parkinson's Disease
Regenerative Medicine Neurology Venture Capital
 HSMN NewsFeed - 5 Nov 2019
A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A To Develop A Pipeline Of Selective Tumor Cell Therapeutics
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Jul 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 28 Jun 2018
BrainStorm Strengthens Executive Management Team with the Appointment of Susan Ward, Ph.D. and Joseph Petroziello
Regenerative Medicine Personnel
 HSMN NewsFeed - 27 Jun 2018
Adicet Bio appoints Stewart Abbot, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Jun 2018
Fortuna Fix Announces Appointment of Madhavan Balachandran to Board of Directors
Regenerative Medicine Personnel
 HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 30 Apr 2018
Adicet Bio appoints Elizabeth "EJ" Read, M.D. as Chief Technology Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Apr 2018
Cellenkos, Inc. Announces Alick Sun as Senior Vice President for Corporate and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2018
BrainStorm Appoints Two Leading Thought Leaders in the Fields of Neuroscience and Regenerative Medicine to its Scientific Advisory Board
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Mar 2018
BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017
Regenerative Medicine Neurology
 HSMN NewsFeed - 5 Feb 2018
BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 2 Nov 2017
BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 16 Oct 2017
BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 17 Aug 2017
BlueRock Therapeutics Expands Toronto Presence with R&D and Manufacturing Hub, Appoints Key R&D Leadership
Regenerative Medicine Personnel
 HSMN NewsFeed - 7 Aug 2017
BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 25 Jul 2017
BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jul 2017
Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Jul 2017
BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn(R) in ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 28 Jun 2017
Adicet Bio Appoints Jesse McGreivy, M.D., Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Mar 2017
BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 27 Feb 2017
BrainStorm Names Dr. June S. Almenoff and Arturo O. Araya to its Board of Directors as Company Prepares for Clinical and Commercial Success
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 21 Feb 2017
BrainStorm Seeking Approval To Distribute NurOwn(R) in Canada
Regenerative Medicine Neurology Regulatory Distribution
 HSMN NewsFeed - 28 Jan 2016
Cynata Receives Favourable Advice from UK Regulatory Authority
Regenerative Medicine Regulatory
 HSMN NewsFeed - 9 Dec 2015
Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics(TM)
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Dec 2015
BrainStorm Cell Therapeutics Announces Appointment of Dr. Revital Geffen-Aricha as Vice President of Research & Development
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 3 Aug 2015
BrainStorm Strengthens Executive Team: Announces the Appointment of Yoram Bibring as Chief Financial Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 19 Mar 2015
Coronado Biosciences Announces the Formation of Mustang Therapeutics, Inc. in Partnership With the City of Hope in Duarte, CA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2014
Cell Therapeutics, Inc. Announces Change of Name to CTI BioPharma Corp.
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2014
BrainStorm and Massachusetts General Hospital Sign Definitive Agreement for ALS Clinical Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 10 Mar 2014
Stem Cell Therapeutics Strengthens its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 30 Jan 2014
Stem Cell Therapeutics Announces Appointment of Dr. Calvin R. Stiller as Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jan 2014
PIXUVRI(R) (pixantrone) Receives Positive Final Appraisal Determination from NICE
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Jan 2014
Cell Therapeutics Announces Removal of the Partial Clinical Hold on Tosedostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Dec 2013
Cell Therapeutics and GKV-SV Reach Agreement on Pricing of PIXUVRI(R) (pixantrone) in Germany
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 31 Oct 2013
Stem Cell Therapeutics Receives U.S. Orphan Drug Designation for the Use of Tigecycline to Treat Acute Myeloid Leukemia
Regenerative Medicine Oncology FDA
 HSMN NewsFeed - 17 Oct 2013
OncoMed Pharmaceuticals Appoints Michael Wyzga to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Oct 2013
Second Draft NICE Guidance for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Aug 2013
Market Access Granted in France for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Market Access Granted in Italy for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 8 Jul 2013
Cell Therapeutics Provides Reimbursement Update for the UK for Aggressive non-Hodgkin Lymphoma Treatment, PIXUVRI(R) (pixantrone)
Biopharmaceuticals Oncology Reimbursement
 HSMN NewsFeed - 26 Jun 2013
Pluristem Enters Into Strategic Partnership and Licensing Agreement With Cha Bio&Diostech for the Development and Commercialization of PLX Cells for the Treatment of CLI and IC in South Korea
Regenerative Medicine Licensing
 HSMN NewsFeed - 28 Mar 2013
Stem Cell Therapeutics Provides Corporate Update on Acquisitions and Financing
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 4 Feb 2013
Stem Cell Therapeutics Announces Agreement With Trillium Therapeutics Inc. for Merger
Regenerative Medicine Mergers & Acquisitions
 HSMN NewsFeed - 28 Jan 2013
BrainStorm Cell Therapeutics Appoints Alon Natanson as Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 10 Dec 2012
Aequus BioPharma Appoints Ronald J. Berenson, M.D. President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Oct 2012
Cell Therapeutics OPAXIOTM Receives Orphan Drug Designation for Malignant Brain Cancer from FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2012
Cell Therapeutics Announces European Launch Of Pixuvri(R) For Treatment Of Adult Patients With Multiply Relapsed Or Refractory Aggressive Non-Hodgkin B-Cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2012
Cell Therapeutics Appoints New Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 31 May 2012
Cell Therapeutics' Pixuvri(R) Phase 3 Clinical Trial Results Published in The Lancet Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Mar 2012
Islet Sciences Names Dr. George J. Todaro and Dr. Jerry L. Nader to Board of Directors
Regenerative Medicine Endocrinology Personnel
 HSMN NewsFeed - 30 Jan 2012
Cell Therapeutics Withdraws New Drug Application for Pixuvri™ and Plans to Resubmit in 2012
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Sep 2011
Independent Radiology Assessment Panel Results Confirm Statistical Significance of Response and Progression Endpoints of Cell Therapeutics' Pixantrone PIX301 Pivotal Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jun 2011
Tetragenetics Announces New CEO and Expands Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Mar 2011
Cell Therapeutics Acquires Exclusive Marketing and Co-Development Rights in the Americas to Chroma Therapeutics' Tosedostat, a First in Class Tumor Selective Oral Therapy for Treatment of Blood Related and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 24 Jan 2011
BrainStorm Appoints Dr. Adrian Harel as Chief Operating Officer and Acting Chief Executive Officer
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 7 Dec 2010
Medistem Announces New Management Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 3 Dec 2010
Cell Therapeutics Files Appeal on FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Nov 2010
Paclitaxel Poliglumex (OPAXIO(R)) Combined with Temozolomide and Radiotherapy Demonstrates High Response Rates with Encouraging Progression Free Survival in Malignant Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2010
European Medicines Agency Approves Pediatric Investigational Plan for Pixuvri
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Sep 2010
Cell Therapeutics to Appeal FDA Decision on New Drug Application (NDA) for Pixantrone to Treat Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Jun 2010
Bayer and OncoMed Pharmaceuticals Enter Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 17 Jun 2010
OncoMed Pharmaceuticals and Bayer Schering Pharma Announce Strategic Alliance to Develop Anti-Cancer Stem Cell Therapeutics
Biopharmaceuticals Regenerative Medicine Oncology
 HSMN NewsFeed - 2 Jun 2010
Alnylam Strengthens Management Team with New Key Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 May 2010
BrainStorm Announces Significant Milestones Achieved and 2009 Review
Regenerative Medicine Neurology
 HSMN NewsFeed - 9 Apr 2010
CTI Receives Complete Response Letter from the FDA for Pixantrone NDA; CTI to File for Expanded Access for Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2009
European Medicines Agency Grants Cell Therapeutics Orphan Drug Designation for Pixantrone in Diffuse Large B-Cell Lymphoma (DLBCL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Dec 2009
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Sep 2009
Cell Therapeutics Applies for European Orphan Drug Designation for Pixantrone in Aggressive Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Aug 2009
BrainStorm Cell Therapeutics Secures Funding to Reach Clinical Trials for ALS
Regenerative Medicine Neurology
 HSMN NewsFeed - 21 Jul 2009
Stem Cell Therapeutics Corp. Receives Green Light to Begin Enrolling Patients in the India Phase IIb Acute Ischemic Stroke Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 7 Jul 2009
OncoMed Pharmaceuticals Appoints Sunil Patel Senior Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 May 2009
Pixantrone Now Available in Europe on a Named-Patient Basis
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2009
Spectrum Pharmaceuticals Poised to Acquire 100% Interest in RIT Oncology LLC Joint Venture upon CTI's Fulfillment of Closing Conditions
Biopharmaceuticals Oncology Acquisitions
 HSMN NewsFeed - 18 Feb 2009
Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Feb 2009
Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jan 2009
Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2009
Treatment with the Zevalin(R) Therapeutic Regimen as Sole Therapy Produces 83 Percent Complete Response Rate in Mucosa-Associated Lymphoid Tissue (MALT) Orbital Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2008
Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Dec 2008
Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Dec 2008
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Nov 2008
Cell Therapeutics' Pixantrone Phase III (EXTEND) Pivotal Trial Successful in Achieving Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
High-Dose Zevalin(R) With Tandem Stem Cell Infusion Produces 87 Percent Overall Survival in Relapsed/Refractory or High Risk Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Oct 2008
Neuralstem Licenses Cleveland Clinic Spinal Cord Injection Technology
Devices Drug Delivery Regenerative Medicine Neurology
 HSMN NewsFeed - 18 Sep 2008
Stem Cell Therapeutics Corp. Receives Letter From Health Canada and Verbal Request From FDA to Place a Clinical Hold on Its REGENESIS Phase IIb Stroke Trial in Canada and the US, Respectively
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 2 Sep 2008
World Renowned ALS Expert From Harvard Medical School and Mass. General Hospital, Dr. Robert H. Brown Jr., Joins BrainStorm Cell Therapeutics Scientific Advisory Board
Regenerative Medicine Personnel
 HSMN NewsFeed - 18 Aug 2008
Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2008
Craig W. Philips Takes Helm at CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Jul 2008
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Jun 2008
CTI Enters Into Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data for Potential U.S. Supplemental Marketing Application
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
Sequential R-CHOP and Ibritumomab Tiuxetan (Zevalin(R)) Regimen Produces Impressive Survival Rates in High Risk Elderly Patients With Untreated Aggressive Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2008
Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2008
Stem Cell Therapeutics Corp. Expands Executive Team by Appointing Thomas Franck as Vice President of Commercial Planning
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 5 May 2008
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Apr 2008
Veteran Drug Industry Executive to Become President of CTI
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Apr 2008
Stem Cell Therapeutics Corp. Receives "May Proceed" From FDA for Its Phase IIb Clinical Stroke Trial and IND
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 2 Apr 2008
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Mar 2008
Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2008
Fludarabine, Mitoxantrone and Zevalin(R) Produces 96% Complete Remission Rate in First-Line Treatment of Patients with Follicular Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Mar 2008
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Feb 2008
Stem Cell Therapeutics Announces Favorable Results From the Phase IIa BETAS Stroke Trial
Regenerative Medicine Neurology
 HSMN NewsFeed - 12 Feb 2008
Cell Therapeutics, Inc. (CTI) Projects Zevalin(R) Sales of $15 Million With Cash Flow Breakeven for Commercial Operations in 2008
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2008
Zevalin(R) Combined With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation (ASCT) Produces High Overall Survival and Progression-Free Survival Rates in Patients With Relapsed Non-Hodgkin's Lymphoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jan 2008
Nastech Appoints Bruce R. York as Interim Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Dec 2007
Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 18 Dec 2007
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 12 Nov 2007
BrainStorm Cell Therapeutics Secures Significant Equity Financing and Raises Research Budget
Regenerative Medicine Neurology
 HSMN NewsFeed - 8 Nov 2007
Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Oct 2007
Velcura Therapeutics, Inc. Appoints Industry Executive to Lead Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Oct 2007
Rami Efrati, Former VP Business Development and Marketing for NICE SYSTEMS' Government Division, Joins BrainStorm As CEO
Regenerative Medicine Neurology Personnel
 HSMN NewsFeed - 8 Oct 2007
BrainStorm on the Verge of a Breakthrough Towards Developing a Cure for Lou Gehrig's Disease
Regenerative Medicine Neurology
 HSMN NewsFeed - 24 Sep 2007
Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Sep 2007
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2007
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Sep 2007
BrainStorm Cell Therapeutics Takes Initial Steps Toward FDA Submission
Regenerative Medicine Neurology
 HSMN NewsFeed - 16 Aug 2007
Cell Therapeutics, Inc. (CTI) Enters Agreement to Acquire Lymphoma Drug Zevalin(R) from Biogen Idec for Sales and Marketing in the United States
Biopharmaceuticals Acquisitions Oncology
 HSMN NewsFeed - 25 Jul 2007
Cell Therapeutics, Inc. (CTI) Announces Agreement to Acquire SMi; Gains Global Rights to Brostallicin, in a New Class of Cancer Killing Agents
Biopharmaceuticals Mergers & Acquisitions Oncology
 HSMN NewsFeed - 16 Jul 2007
BrainStorm Cell Therapeutics Elects Moshe Lion to Its Board of Directors
Regenerative Medicine Personnel
 HSMN NewsFeed - 11 Jul 2007
StemCyte Appoints Robert Dickey IV as Senior Vice President and Chief Financial Officer
Regenerative Medicine Personnel
 HSMN NewsFeed - 5 Jun 2007
XYOTAX(TM) More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pre-menopausal Estrogen Levels Linked to Higher Death Rate Among Women Receiving Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2007
Cell Therapeutics, Inc. Receives FDA Special Protocol Assessment (SPA) Comments on the Design of Phase III Trial of Pixantrone in Relapsed Indolent NHL
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 May 2007
Former Immunex Management Team Chosen to Head-Up CTI Subsidiary Aequus BioPharma, Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2007
Bill Cadwallader Joins Velcura Therapeutics, Inc. as Executive Vice President of Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2007
Pixantrone Granted Fast Track Designation by FDA for Relapsed Indolent NHL Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Apr 2007
Osprey Pharmaceuticals Limited Appoints Jack M. Anthony to the Newly Created Position of Senior Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2007
Cell Therapeutics, Inc. (CTI) Announces XYOTAX(TM) Has Fast Track Designation for Women With Advanced Lung Cancer Who Are Performance Status 2 (PS2)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Apr 2007
NeoStem Announces Launch of Government Affairs Initiative
Regenerative Medicine
 HSMN NewsFeed - 20 Mar 2007
Cell Therapeutics Inc. (CTI) Files for Special Protocol Assessment (SPA) for XYOTAX(TM) PGT307 Lung Cancer Trial in Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 15 Mar 2007
NeoStem Hires Experienced Marketing Executive Arlene Graime to Direct Government Affairs and Raise Nationwide Consumer Awareness
Regenerative Medicine Personnel
 HSMN NewsFeed - 13 Mar 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 26 Feb 2007
'Encouraging' Major Responses Seen With XYOTAX(TM) in Patients With Taxane-Resistant Androgen Independent Prostate Cancer
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2007
Cell Therapeutics, Inc. (CTI) Spin-off to Use Proprietary Recombinant Genetic Technology to Develop Novel Biopharmaceuticals, Follow-on Biologics and to Deliver siRNA
Biopharmaceuticals
 HSMN NewsFeed - 1 Feb 2007
Xencor Appoints Jade R. Brown as Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Jan 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Northern Therapeutics and MaxCyte Initiate Landmark Engineered Cell Therapy Trial for Fatal Lung Disease
Biopharmaceuticals Regenerative Medicine
 HSMN NewsFeed - 12 Dec 2006
Cell Therapeutics, Inc. (CTI) Announces Pixantrone Combination Regimen Produces High Response Rates
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2006
'Impressive' Complete Remission and 'Durable' Survival Data in Relapsed Indolent NHL Patients Identifies New Potential Registration Trial for Pixantrone
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Nov 2006
Pfizer Inc Vice President of Corporate Policy and Strategic Management, Fred Telling, to Join Board of Directors of Cell Therapeutics, Inc. (CTI)
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2006
Elbit Medical Group Announces Receipt of a Special Protocol Assessment From the FDA to Gamida Cell's Stemex(R) Registration Study
Regenerative Medicine FDA
 HSMN NewsFeed - 3 Nov 2006
Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Nov 2006
Gamida Cell's StemEx(R) Registration Study Receives Special Protocol Assessment from the FDA
Regenerative Medicine FDA
 HSMN NewsFeed - 26 Oct 2006
NeoStem, Inc. Appoints Julio C. Guerra, MD, ABP, as Director of Sales and Marketing
Regenerative Medicine Personnel
 HSMN NewsFeed - 18 Sep 2006
Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 13 Sep 2006
MaxCyte Strengthens Leadership Team
Regenerative Medicine Personnel
 HSMN NewsFeed - 1 Sep 2006
Cell Therapeutics Announces New Bresso Management Structure
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Aug 2006
StemCells, Inc. Grants License to Stem Cell Therapeutics
Regenerative Medicine Licensing
 HSMN NewsFeed - 23 Aug 2006
PrimeCell(TM) Therapeutics Partners with Regeneration Technologies, Inc. to Co-Develop Stem Cell Product for Orthopedic Applications
Devices Orthopaedic Regenerative Medicine
 HSMN NewsFeed - 8 Aug 2006
Cell Therapeutics, Inc. (CTI) Announces Encouraging Pixantrone Phase III Interim Data
Biopharmaceuticals Onocology
 HSMN NewsFeed - 7 Jun 2006
CTI to File for XYOTAX(TM) Marketing Approval in Europe on Equivalent Effectiveness (Non-Inferiority) and Superior Safety Using Existing STELLAR Clinical Trial Data
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 4 Jun 2006
Data from XYOTAX(TM) STELLAR Trials Presented at 2006 Meeting of American Society of Clinical Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2006
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 May 2006
Stem Cell Therapeutics Corp. Announces Issuance of Second US Patent
Regenerative Medicine
 HSMN NewsFeed - 1 May 2006
World-Renowned Safety Consultant Joy A. Cavagnaro Joins BrainStorm Cell Therapeutics
Regenerative Medicine Personnel
 HSMN NewsFeed - 10 Apr 2006
StemCells, Inc. Names Elizabeth Leininger Vice President, Regulatory Affairs and Quality Assurance
Biopharmaceuticals Regenerative Medicine Personnel
 HSMN NewsFeed - 22 Mar 2006
Pixantrone Combination Regimen Produces High Rates of Complete Remission for Patients With Aggressive NHL Who Fail CHOP Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Feb 2006
Cell Therapeutics, Inc. Hires Former BIO VP of Communications
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Feb 2006
XYOTAX(TM) has FDA Fast Track Designation for Women With Advanced Lung Cancer Who are Performance Status 2
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 20 Jan 2006
Stem Cell Therapeutics Corp. Announces Selected Upcoming Development Milestones
Biopharmaceuticals Regenerative Medicine Neurology
 HSMN NewsFeed - 17 Jan 2006
Pharmix Announces Appointment of Jack M. Anthony as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jan 2006
Gamida Cell Announces New Supporting Evidence That an Ex-Vivo Expanded Population of Human Bone Marrow Stem Cells May Help Treat Heart Disease
Biopharmaceuticals Regenerative Medicine Cardiology
Return to NewsFeed  

 Additional items found! 96

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 96 additional stories matching:
Cell Therapeutics
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.